Real-world evaluation of the clinical safety and efficacy of fluticasone/formoterol FDC via the Revolizer® in patients with persistent asthma in India.
Administration, Inhalation
Adult
Aged
Aged, 80 and over
Asthma
/ drug therapy
Bronchodilator Agents
/ adverse effects
Drug Combinations
Dry Powder Inhalers
Female
Fluticasone
/ adverse effects
Formoterol Fumarate
/ adverse effects
Humans
India
Male
Middle Aged
Peak Expiratory Flow Rate
Prospective Studies
Surveys and Questionnaires
Airway inflammation
Asthma
DPI
Dry powder inhaler
FDC
Fixed-dose combination
Fluticasone/formoterol
PEFR
Peak expiratory flow rate
Journal
Pulmonary pharmacology & therapeutics
ISSN: 1522-9629
Titre abrégé: Pulm Pharmacol Ther
Pays: England
ID NLM: 9715279
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
13
08
2019
revised:
25
11
2019
accepted:
25
11
2019
pubmed:
4
12
2019
medline:
13
2
2021
entrez:
4
12
2019
Statut:
ppublish
Résumé
The combination of inhaled corticosteroids (ICS) and long-acting beta
Identifiants
pubmed: 31794836
pii: S1094-5539(19)30184-1
doi: 10.1016/j.pupt.2019.101869
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Drug Combinations
0
fluticasone-formoterol
0
Fluticasone
CUT2W21N7U
Formoterol Fumarate
W34SHF8J2K
Types de publication
Clinical Trial
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
101869Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.